A study of COTI-219.
Phase of Trial: Phase I
Latest Information Update: 16 Jan 2017
At a glance
- Drugs COTI 219 (Primary)
- Indications Cancer; Colorectal cancer; Small cell lung cancer
- Focus Adverse reactions
- 16 Jan 2017 Indications are assumed from RDI profile.
- 16 Jan 2017 New trial record
- 10 Jan 2017 Critical Outcome Technologies plans to file an IND application with the US FDA in late 2017.